Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early infliximab treatment for hip arthritis associated with ankylosing spondylitis
2009-016587-36Phase 4Terminated
- Sponsor
- Merck & Co.
- Start
- Jan 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of infliximab in ankylosing spondylitis (AS), sponsored by Merck & Co. Primary endpoint: Clinical improvement in hip involvement by WOMAC. Started Jan 2010; status: terminated.
02
Drugs
infliximab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2009-016587-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016587-36.